Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.38 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | ABCC8 | Q09428 | 4/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 4/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27537241 | 0.89 | PDE7A (0.43) | PDE7AALDH1A1FFAR4EPAS1VEGFA | |
| SCHEMBL11481766 | 0.89 | FFAR4 (0.44) | PDE7AALDH1A1FFAR4EPAS1ABCC8 | |
| SCHEMBL11122753 | 0.87 | ALDH1A1 (0.45) | PDE7AALDH1A1EPAS1ABCC8KCNJ11 | |
| SCHEMBL28113676 | 0.87 | ALDH1A1 (0.45) | PDE7AALDH1A1FFAR4EPAS1ABCC8 | |
| SCHEMBL18980365 | 0.85 | ALDH1A1 (0.40) | PDE7AALDH1A1FFAR4EPAS1VEGFA | |
| SCHEMBL27645588 | 0.85 | ALDH1A1 (0.46) | PDE7AALDH1A1FFAR4EPAS1VEGFA | |
| SCHEMBL27323607 | 0.85 | ALDH1A1 (0.43) | PDE7AALDH1A1FFAR4EPAS1VEGFA | |
| SCHEMBL11136494 | 0.82 | FFAR4 (0.42) | PDE7AALDH1A1FFAR4EPAS1VEGFA | |
| SCHEMBL3949941 | 0.79 | ALDH1A1 (0.36) | PDE7AALDH1A1FFAR4EPAS1VEGFA | |
| SCHEMBL504875 | 0.77 | EPAS1 (0.40) | PDE7AALDH1A1FFAR4EPAS1ABCC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318561-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-2576540-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3318561-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
| US-9834564-B2 | Substituted quinolines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834564-B2 | Substituted quinolines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834564-B2 | Substituted quinolines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-06-18 | — | — | US | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969349-B2 | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2576540-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150156-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011150156-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037590-A1 | SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS | PDE10A, PDE2A, PDE3A | PDE7A 14/4885ALDH1A1 559/4885FFAR4 2460/4885 |
| US-20130158003-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | PDE7A 3224/4885ALDH1A1 560/4885FFAR4 1202/4885 |
| US-10562916-B2 | Substituted quinoxalines as PDE-10 inhibitors | PDE4A, PDE2A, PDE9A | PDE7A 7/4885ALDH1A1 1140/4885FFAR4 2616/4885 |
| US-20150166571-A1 | Heteroaryl Compounds and Methods of Use Thereof | COMT, GPR119, NLN | PDE7A 3224/4885ALDH1A1 560/4885FFAR4 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.